Product Overview
Dragon Pharma Toremfine is toremifene citrate in 20 mg tablets, a selective estrogen receptor modulator sold under the name Fareston in oncology, where the licensed dose is 60 mg a day for breast cancer. The pack here is one third of that strength, which matters when reading any protocol: dose figures must be counted in tablets rather than assumed from the medical label. Within this catalogue the compound belongs to the recovery group rather than to the anabolic group, alongside Nolvadex and Clomid.
Mechanically a SERM is a blocker with a partial signal. Toremifene occupies estrogen receptors in tissue such as breast tissue without delivering the full estrogen message, which is how it reduces estrogenic effects, and at the same time it interferes with the negative feedback that estrogen sends to the pituitary. The result is a rise in LH and FSH, the two hormones that tell the testes to produce testosterone again. That is the whole reason the compound is used after a cycle: it does not add testosterone, it asks the body to make its own. Because it does not aromatise and does not itself hold water, none of the swelling or blood-pressure issues of an aromatisable cycle apply to it.
The kinetics are long. Toremifene has an elimination half-life of 3 to 7 days, and its metabolites are measurable from 4 to 21 days, so a course keeps working well past the final tablet and a repeat protocol cannot simply be stacked on the week after. In hepatic impairment the label records the mean half-life rising less than twofold, still a reason to know liver status. Two consequences follow: once-daily dosing is enough, and the wash-out between protocols has to be respected.
Dosage Protocol
Figures below are counted against the 20 mg tablet on this page, which is smaller than the 60 mg medical form. The sports values come from the project reference data for toremifene; the manufacturer label only describes the oncology schedule.
| Beginner | 20-40 mg a day, which is one or two tablets, across four to six weeks; no verified sports protocol exists, so this band is the lower reference range |
| Intermediate | 40-60 mg a day, two to three tablets, for four to six weeks; 60 mg is the medical tablet strength |
| Advanced | 60 mg a day, three tablets, for four to six weeks, which is the top of the medical dose; higher figures are not supported by any source consulted |
| Female | No female protocol is documented for this compound in a training context, so none is quoted here |
| Administration | Oral tablets, once a day at the same time, with or without food; the long half-life removes any need for split dosing |
Because the half-life is measured in days, a missed dose does not empty the system, and doubling up only raises the peak. Counting in whole tablets avoids treating the 20 mg pack as if it were the 60 mg medical form.
Recovery and Gynecomastia Protocols
Toremifene is used in two situations in a training context, and both are off-label. The first is restarting the axis after a cycle; the second is controlling estrogenic breast symptoms while a cycle is still running.
The alternative blockers in the same section are Nolvadex and Clomid, while the aromatase side is covered by Aromasin and Femara. The choice between a blocker and an aromatase inhibitor depends on whether the problem is the hormone level or the receptor response.
What to Expect
- Week one of therapy. LH and FSH rise, as they do with every SERM; the hormonal signal comes before the symptom change.
- Early weeks. Estrogenic symptoms such as puffiness and tenderness ease, though breast tissue can feel more sensitive before it settles.
- Weeks two to four. The body's own testosterone production climbs back, which is the measurable outcome rather than a feeling of recovery.
- Weeks four to six. A standard protocol window closes here, and a blood panel is what confirms it did the job.
- Effect outlasts the tablets. Metabolites are measurable for 4 to 21 days, so a second protocol starts later than the calendar suggests.
- Limitation. Toremifene is not approved as a recovery drug; this is an oncology SERM used off-label, and the sports dosing quoted above is reference data rather than a validated protocol.
- Limitation. No receptor blocker can bring an axis back while circulating androgen still holds it down, so the pause after the final injection belongs to the plan rather than being a delay.
Side Effects and Management
The profile is the class profile of a selective estrogen receptor modulator, plus one item specific to hepatic clearance. Hot flushes and nausea are everyday complaints; clotting risk is the one that justifies stopping.
Monitoring After Therapy Ends
Recovery is a number, not a mood. The rows below set out when the protocol starts, what the two dose routes look like on this pack, and what the closing blood panel has to show.
